Exploring the immune mediators of early pregnancy prospectively may help to identify new early interventions that will increase the likelihood of success and help women make informed decisions regarding their pregnancies.
Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF), protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results will be correlated with IVF outcomes.
Study Type
OBSERVATIONAL
Enrollment
500
Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
New York, New York, United States
To explore the relationship between immune mediators and IVF outcome prospectively in women who receive in vitro fertilization treatment.
Time frame: 35 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.